2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
385
Myelodysplastic Syndromes
160
Leukemia, Myelomonocytic, Chronic
76
Leukemia
65
Recurrence
32
Myeloproliferative Disorders
23
Hematologic Neoplasms
20
Neoplasms
19
Multiple Myeloma
17
Carcinoma, Non-Small-Cell Lung
17
Lymphoma, Non-Hodgkin
16
Lymphoma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Lymphoma, Large B-Cell, Diffuse
14
Anemia, Refractory, with Excess of Blasts
14
Lymphoma, T-Cell, Peripheral
13
Primary Myelofibrosis
12
Neoplasm, Residual
12
Leukemia, Monocytic, Acute
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Leukemia, Biphenotypic, Acute
11
Leukemia, Myelomonocytic, Acute
10
Hodgkin Disease
10
Myelodysplastic-Myeloproliferative Diseases
9
Leukemia, Erythroblastic, Acute
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Myeloid
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia, Megakaryoblastic, Acute
8
Congenital Abnormalities
8
Interventions
fludarabine phosphate
6
Whole-Body Irradiation
5
Therapeutics
5
Mycophenolic Acid
5
Cyclosporine
5
Psychiatric Rehabilitation
4
Peripheral Blood Stem Cell Transplantation
4
midostaurin
3
avapritinib
2
Sunitinib
2
Pentetic Acid
2
Methotrexate
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Busulfan
2
thymoglobulin
1
ripretinib
1
liposomal doxorubicin
1
ibrutinib
1
hydrocortisone valerate
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
ethanolamine oleate
1
denileukin diftitox
1
Valganciclovir
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Thiotepa
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Mast-Cell
×
Azacitidine
×
Clear all
NCT05609942
2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1
Terminated
9 enrolled